ecancer

Intraoperative Radiotherapy

Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal

25 Sep 2022

Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

21 Sep 2022

Cancer survivors' stories: An African perspective

Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation

15 Sep 2022

ESMO 2022: Breast and ovarian trial analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

14 Sep 2022

ESMO 2022: Highlights, commentary and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

12 Sep 2022

ESMO 2022: Breast cancer highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

12 Sep 2022

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data

Prof Matthew P Goetz - Mayo Clinic, Rochester, USA

12 Sep 2022

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial

Prof Matthew P Goetz - Mayo Clinic, Rochester, USA

12 Sep 2022

Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast cancer

Dr Iris Nederlof - The Netherlands Cancer Institute, Amsterdam, Netherlands

12 Sep 2022

A new era of early cancer detection with blood test may change cancer screening paradigms

Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA

11 Sep 2022

New era of early cancer detection blood tests on the horizon

Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA

11 Sep 2022

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update

Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA

11 Sep 2022

More from ecancer